Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin

Akulapalli Sudhakar, Pia Nyberg, Venkateshwar G. Keshamouni, Arjuna P. Mannam, Jian Li, Hikaru Sugimoto, Dominic E Cosgrove, Raghu Kalluri

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Human noncollagenous domain 1 of the α-chain of type IV collagen [α1(IV)NC1], or arresten, is derived from the carbosy terminal of type IV collagen. It was shown, to inhibit angiogenesis and tumor growth in vivo; however, the mechanisms involved are not known. In the present study we demonstrate that human, α1(IV)NC1 binds to α1β1 integrin, competes with type IV collagen binding to α1β1 integrin, and inhibits migration, proliferation, and tube formation by ECs. Also, α1(IV)NC1 pretreatment inhibited FAK/c-Raf/MEK/ERK1/2/p38 MAPK activation in ECs but had no effect on the PI3K/Akt pathway. In contrast, α1(IV)NC1 did not affect proliferation, migration, or the activation of FAK/c-Raf/MEK1/2/p38/ERK1 MAPK pathway in α1 integrin receptor knockout ECs. Consistent with this, α1(IV)NC1 elicited significant antiangiogenic effects and tumor growth inhibition in vivo but failed to do the same in α1 integrin receptor knockout mice. This suggests a highly specific, α1β1 integrin-dependent antiangiogenic activity of α1(IV)NC1. In addition, α1(IV)NC1 inhibited hypoxia-induced expression of hypoxia-inducible factor 1α and VEGF in ECs cultured on type IV collagen by inhibiting ERK1/2 and p38 activation. This unravels a hitherto unknown function of human α1(IV)NC1 and suggests a critical role for integrins in hypoxia and hypoxia-induced angiogenesis. Collectively, the above data indicate that α1(IV)NC1 is a potential therapeutic candidate for targeting tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)2801-2810
Number of pages10
JournalJournal of Clinical Investigation
Volume115
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Collagen Type I
Integrins
Collagen Type IV
p38 Mitogen-Activated Protein Kinases
Hypoxia-Inducible Factor 1
Neoplasms
Mitogen-Activated Protein Kinase Kinases
Growth
Phosphatidylinositol 3-Kinases
Knockout Mice
Vascular Endothelial Growth Factor A
Hypoxia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sudhakar, A., Nyberg, P., Keshamouni, V. G., Mannam, A. P., Li, J., Sugimoto, H., ... Kalluri, R. (2005). Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. Journal of Clinical Investigation, 115(10), 2801-2810. https://doi.org/10.1172/JCI24813

Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. / Sudhakar, Akulapalli; Nyberg, Pia; Keshamouni, Venkateshwar G.; Mannam, Arjuna P.; Li, Jian; Sugimoto, Hikaru; Cosgrove, Dominic E; Kalluri, Raghu.

In: Journal of Clinical Investigation, Vol. 115, No. 10, 10.2005, p. 2801-2810.

Research output: Contribution to journalArticle

Sudhakar, A, Nyberg, P, Keshamouni, VG, Mannam, AP, Li, J, Sugimoto, H, Cosgrove, DE & Kalluri, R 2005, 'Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin', Journal of Clinical Investigation, vol. 115, no. 10, pp. 2801-2810. https://doi.org/10.1172/JCI24813
Sudhakar, Akulapalli ; Nyberg, Pia ; Keshamouni, Venkateshwar G. ; Mannam, Arjuna P. ; Li, Jian ; Sugimoto, Hikaru ; Cosgrove, Dominic E ; Kalluri, Raghu. / Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. In: Journal of Clinical Investigation. 2005 ; Vol. 115, No. 10. pp. 2801-2810.
@article{613a4fa3274e49ca94e79f42dde83e26,
title = "Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin",
abstract = "Human noncollagenous domain 1 of the α-chain of type IV collagen [α1(IV)NC1], or arresten, is derived from the carbosy terminal of type IV collagen. It was shown, to inhibit angiogenesis and tumor growth in vivo; however, the mechanisms involved are not known. In the present study we demonstrate that human, α1(IV)NC1 binds to α1β1 integrin, competes with type IV collagen binding to α1β1 integrin, and inhibits migration, proliferation, and tube formation by ECs. Also, α1(IV)NC1 pretreatment inhibited FAK/c-Raf/MEK/ERK1/2/p38 MAPK activation in ECs but had no effect on the PI3K/Akt pathway. In contrast, α1(IV)NC1 did not affect proliferation, migration, or the activation of FAK/c-Raf/MEK1/2/p38/ERK1 MAPK pathway in α1 integrin receptor knockout ECs. Consistent with this, α1(IV)NC1 elicited significant antiangiogenic effects and tumor growth inhibition in vivo but failed to do the same in α1 integrin receptor knockout mice. This suggests a highly specific, α1β1 integrin-dependent antiangiogenic activity of α1(IV)NC1. In addition, α1(IV)NC1 inhibited hypoxia-induced expression of hypoxia-inducible factor 1α and VEGF in ECs cultured on type IV collagen by inhibiting ERK1/2 and p38 activation. This unravels a hitherto unknown function of human α1(IV)NC1 and suggests a critical role for integrins in hypoxia and hypoxia-induced angiogenesis. Collectively, the above data indicate that α1(IV)NC1 is a potential therapeutic candidate for targeting tumor angiogenesis.",
author = "Akulapalli Sudhakar and Pia Nyberg and Keshamouni, {Venkateshwar G.} and Mannam, {Arjuna P.} and Jian Li and Hikaru Sugimoto and Cosgrove, {Dominic E} and Raghu Kalluri",
year = "2005",
month = "10",
doi = "10.1172/JCI24813",
language = "English (US)",
volume = "115",
pages = "2801--2810",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin

AU - Sudhakar, Akulapalli

AU - Nyberg, Pia

AU - Keshamouni, Venkateshwar G.

AU - Mannam, Arjuna P.

AU - Li, Jian

AU - Sugimoto, Hikaru

AU - Cosgrove, Dominic E

AU - Kalluri, Raghu

PY - 2005/10

Y1 - 2005/10

N2 - Human noncollagenous domain 1 of the α-chain of type IV collagen [α1(IV)NC1], or arresten, is derived from the carbosy terminal of type IV collagen. It was shown, to inhibit angiogenesis and tumor growth in vivo; however, the mechanisms involved are not known. In the present study we demonstrate that human, α1(IV)NC1 binds to α1β1 integrin, competes with type IV collagen binding to α1β1 integrin, and inhibits migration, proliferation, and tube formation by ECs. Also, α1(IV)NC1 pretreatment inhibited FAK/c-Raf/MEK/ERK1/2/p38 MAPK activation in ECs but had no effect on the PI3K/Akt pathway. In contrast, α1(IV)NC1 did not affect proliferation, migration, or the activation of FAK/c-Raf/MEK1/2/p38/ERK1 MAPK pathway in α1 integrin receptor knockout ECs. Consistent with this, α1(IV)NC1 elicited significant antiangiogenic effects and tumor growth inhibition in vivo but failed to do the same in α1 integrin receptor knockout mice. This suggests a highly specific, α1β1 integrin-dependent antiangiogenic activity of α1(IV)NC1. In addition, α1(IV)NC1 inhibited hypoxia-induced expression of hypoxia-inducible factor 1α and VEGF in ECs cultured on type IV collagen by inhibiting ERK1/2 and p38 activation. This unravels a hitherto unknown function of human α1(IV)NC1 and suggests a critical role for integrins in hypoxia and hypoxia-induced angiogenesis. Collectively, the above data indicate that α1(IV)NC1 is a potential therapeutic candidate for targeting tumor angiogenesis.

AB - Human noncollagenous domain 1 of the α-chain of type IV collagen [α1(IV)NC1], or arresten, is derived from the carbosy terminal of type IV collagen. It was shown, to inhibit angiogenesis and tumor growth in vivo; however, the mechanisms involved are not known. In the present study we demonstrate that human, α1(IV)NC1 binds to α1β1 integrin, competes with type IV collagen binding to α1β1 integrin, and inhibits migration, proliferation, and tube formation by ECs. Also, α1(IV)NC1 pretreatment inhibited FAK/c-Raf/MEK/ERK1/2/p38 MAPK activation in ECs but had no effect on the PI3K/Akt pathway. In contrast, α1(IV)NC1 did not affect proliferation, migration, or the activation of FAK/c-Raf/MEK1/2/p38/ERK1 MAPK pathway in α1 integrin receptor knockout ECs. Consistent with this, α1(IV)NC1 elicited significant antiangiogenic effects and tumor growth inhibition in vivo but failed to do the same in α1 integrin receptor knockout mice. This suggests a highly specific, α1β1 integrin-dependent antiangiogenic activity of α1(IV)NC1. In addition, α1(IV)NC1 inhibited hypoxia-induced expression of hypoxia-inducible factor 1α and VEGF in ECs cultured on type IV collagen by inhibiting ERK1/2 and p38 activation. This unravels a hitherto unknown function of human α1(IV)NC1 and suggests a critical role for integrins in hypoxia and hypoxia-induced angiogenesis. Collectively, the above data indicate that α1(IV)NC1 is a potential therapeutic candidate for targeting tumor angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=26444475881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444475881&partnerID=8YFLogxK

U2 - 10.1172/JCI24813

DO - 10.1172/JCI24813

M3 - Article

C2 - 16151532

AN - SCOPUS:26444475881

VL - 115

SP - 2801

EP - 2810

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -